Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.

Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL
J Clin Oncol. 2007 25 (5): 493-500

PMID: 17290056 · DOI:10.1200/JCO.2005.02.3879

MeSH Terms (25)

Acute Disease Adolescent Antineoplastic Combined Chemotherapy Protocols Chelating Agents Cohort Studies Enzyme Inhibitors Female Follow-Up Studies Heart Diseases Hodgkin Disease Humans Incidence Leukemia, Myeloid Lung Diseases Male Myelodysplastic Syndromes Neoplasms, Second Primary Neoplasm Staging Osteosarcoma Razoxane Risk Assessment Risk Factors Thyroid Neoplasms Time Factors Topoisomerase II Inhibitors

Connections (1)

This publication is referenced by other Labnodes entities:

Links